Timothy Bhatt

Timothy Bhatt investigates checkpoint immunotherapy for gastric and gastroesophageal junction (GEJ) cancers. His research has contributed to pivotal clinical trials establishing nivolumab combination chemotherapy and pembrolizumab combination regimens as standards of care in HER2-negative and PD-L1-expressing advanced gastric and GEJ cancers. He has characterized the molecular features of gastric cancers that predict immunotherapy benefit including EBV positivity, MSI-high status, and high combined positive PD-L1 scores. His translational work investigates combination immunotherapy strategies including anti-VEGF plus checkpoint blockade in gastric cancer to improve response rates and durability in this high-unmet-need disease.